Tamoxifen (TAM) has been used as an agent for the treatment and prevention of breast cancer. However, long-term treatment of TAM in women increases a risk of developing endometrial cancer. The secondary cancer may be due to the genotoxicity of TAM. To find safer alternatives, four selective estrogen receptor modulators (SERMs), 4-hydroxytamoxifen (4-OHTAM), toremifene (TOR), raloxifene (RAL) and ICI 182,780, were administered to rats with an equimolar dose of TAM [54 μmol/kg (20 mg/kg)/day, p.o. for 7 days]. To evaluate the genotoxicity of each SERMs, the presence of bulky DNA adducts was determined by 32 P-postlabeling/polyacrylamide gel electrophoresis and 32 P-postlabeling/high performance liquid chromatography. The formation of 7,8-dihydro-8-oxodeoxyguanosine (8-oxodG) was analyzed as a marker of typical oxidative damage, using liquid chromatography electrospray tandem mass spectrometry. Among the SERMs, bulky DNA adducts were detected in the liver of rats treated with TAM; total amounts of TAM-DNA adducts was 26.1 adducts/10 7 nucleotides. However, with a detection limit of ~2 adducts/10 9 nucleotides, no bulky DNA adducts were observed with 4-OHTAM, TOR, RAL or ICI 182,780. In addition, no significant increase of hepatic 8-oxodG lesions was detected in rats treated with any of the antiestrogens. Therefore, TOR, RAL and ICI 182,780 are likely to be less genotoxic than TAM.